Sanofi Reconciled Depreciation vs Other Operating Expenses Analysis
SNY Stock | USD 48.67 0.15 0.31% |
Sanofi ADR financial indicator trend analysis is much more than just breaking down Sanofi ADR prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Sanofi ADR is a good investment. Please check the relationship between Sanofi ADR Reconciled Depreciation and its Other Operating Expenses accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sanofi ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Sanofi Stock please use our How to Invest in Sanofi ADR guide.
Reconciled Depreciation vs Other Operating Expenses
Reconciled Depreciation vs Other Operating Expenses Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Sanofi ADR Reconciled Depreciation account and Other Operating Expenses. At this time, the significance of the direction appears to have very week relationship.
The correlation between Sanofi ADR's Reconciled Depreciation and Other Operating Expenses is 0.27. Overlapping area represents the amount of variation of Reconciled Depreciation that can explain the historical movement of Other Operating Expenses in the same time period over historical financial statements of Sanofi ADR, assuming nothing else is changed. The correlation between historical values of Sanofi ADR's Reconciled Depreciation and Other Operating Expenses is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Reconciled Depreciation of Sanofi ADR are associated (or correlated) with its Other Operating Expenses. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Operating Expenses has no effect on the direction of Reconciled Depreciation i.e., Sanofi ADR's Reconciled Depreciation and Other Operating Expenses go up and down completely randomly.
Correlation Coefficient | 0.27 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Reconciled Depreciation
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Sanofi ADR. It is also known as Sanofi ADR overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most indicators from Sanofi ADR's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Sanofi ADR current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sanofi ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Sanofi Stock please use our How to Invest in Sanofi ADR guide.At this time, Sanofi ADR's Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to rise to about 203.7 M in 2024, despite the fact that Discontinued Operations is likely to grow to (110.3 M).
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 26.9B | 31.7B | 26.5B | 21.8B | Total Revenue | 39.2B | 45.4B | 43.1B | 31.0B |
Sanofi ADR fundamental ratios Correlations
Click cells to compare fundamentals
Sanofi ADR Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Sanofi ADR fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 112.7B | 114.5B | 120.2B | 124.6B | 126.5B | 88.2B | |
Short Long Term Debt Total | 25.9B | 23.7B | 22.4B | 21.2B | 18.4B | 13.7B | |
Other Current Liab | 298M | 32M | 127M | 425M | 13.9B | 14.6B | |
Total Current Liabilities | 20.4B | 19.3B | 21.3B | 24.0B | 24.2B | 14.3B | |
Total Stockholder Equity | 58.9B | 63.0B | 68.7B | 73.1B | 74.0B | 50.2B | |
Property Plant And Equipment Net | 11.0B | 10.6B | 12.0B | 11.7B | 11.8B | 8.5B | |
Net Debt | 16.5B | 9.8B | 12.3B | 8.5B | 9.7B | 7.6B | |
Accounts Payable | 15.3B | 15.4B | 17.4B | 18.8B | 7.3B | 9.1B | |
Cash | 9.4B | 13.9B | 10.1B | 12.7B | 8.7B | 6.1B | |
Non Current Assets Total | 83.8B | 80.7B | 89.6B | 90.5B | 95.8B | 66.2B | |
Non Currrent Assets Other | (5.4B) | (4.0B) | (4.4B) | (5.1B) | 738M | 774.9M | |
Cash And Short Term Investments | 9.4B | 13.9B | 10.1B | 12.7B | 8.7B | 6.9B | |
Net Receivables | 10.1B | 1.2B | 612M | 374M | 11.0B | 6.4B | |
Good Will | 44.5B | 44.4B | 48.1B | 49.9B | 49.4B | 33.9B | |
Common Stock Shares Outstanding | 1.3B | 1.3B | 1.3B | 1.3B | 1.3B | 1.3B | |
Short Term Investments | 426M | 900M | 1.1B | 664M | 270M | 256.5M | |
Liabilities And Stockholders Equity | 112.7B | 114.5B | 120.2B | 124.6B | 126.5B | 88.2B | |
Non Current Liabilities Total | 33.2B | 32.1B | 29.9B | 27.1B | 27.9B | 23.5B | |
Inventory | 19.2B | 18.6B | 19.9B | 20.9B | 9.7B | 11.4B | |
Other Current Assets | (9.8B) | 83M | 89M | 85M | 1.2B | 1.0B | |
Other Stockholder Equity | (47.9B) | (56.4B) | (59.0B) | (64.3B) | (871M) | (827.5M) | |
Total Liab | 53.4B | 51.2B | 51.2B | 51.6B | 52.1B | 37.8B | |
Property Plant And Equipment Gross | 11.0B | 10.6B | 12.0B | 11.7B | 27.4B | 28.8B | |
Total Current Assets | 28.9B | 33.8B | 30.7B | 34.1B | 30.7B | 22.0B | |
Accumulated Other Comprehensive Income | 52.6B | 56.7B | 62.2B | 68.2B | 4.9B | 4.6B | |
Short Term Debt | 4.8B | 3.0B | 3.5B | 4.5B | 2.3B | 2.9B | |
Intangible Assets | 16.6B | 18.4B | 21.4B | 21.6B | 73.6B | 77.3B | |
Other Liab | 12.1B | 11.4B | 11.0B | 10.8B | 12.5B | 11.9B | |
Current Deferred Revenue | 3.8B | 822M | 319M | 264M | 597M | 567.2M | |
Retained Earnings | 51.8B | 60.1B | 63.0B | 66.7B | 67.5B | 64.1B | |
Other Assets | 8.8B | 11.4B | 13.5B | 12.9B | 14.8B | 9.8B | |
Long Term Debt | 20.1B | 19.7B | 17.1B | 14.9B | 14.3B | 12.7B | |
Property Plant Equipment | 11.0B | 10.6B | 12.0B | 11.7B | 13.4B | 10.5B | |
Deferred Long Term Liab | 2.3B | 6.1B | 7.7B | 6.2B | 7.2B | 4.0B | |
Long Term Investments | 5.3B | 7.1B | 8.0B | 9.2B | 2.7B | 2.5B | |
Short Long Term Debt | 4.6B | 2.8B | 3.2B | 4.2B | 2.0B | 3.2B | |
Net Tangible Assets | 177M | 6.3B | 6.9B | 9.5B | 8.5B | 4.6B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.C | Citigroup | |
CRM | Salesforce | |
MSFT | Microsoft |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sanofi ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Sanofi Stock please use our How to Invest in Sanofi ADR guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Complementary Tools for Sanofi Stock analysis
When running Sanofi ADR's price analysis, check to measure Sanofi ADR's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sanofi ADR is operating at the current time. Most of Sanofi ADR's value examination focuses on studying past and present price action to predict the probability of Sanofi ADR's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sanofi ADR's price. Additionally, you may evaluate how the addition of Sanofi ADR to your portfolios can decrease your overall portfolio volatility.
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |
Is Sanofi ADR's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sanofi ADR. If investors know Sanofi will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sanofi ADR listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.43) | Earnings Share 1.95 | Revenue Per Share 18.492 | Quarterly Revenue Growth 0.023 | Return On Assets 0.0454 |
The market value of Sanofi ADR is measured differently than its book value, which is the value of Sanofi that is recorded on the company's balance sheet. Investors also form their own opinion of Sanofi ADR's value that differs from its market value or its book value, called intrinsic value, which is Sanofi ADR's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sanofi ADR's market value can be influenced by many factors that don't directly affect Sanofi ADR's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sanofi ADR's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sanofi ADR is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sanofi ADR's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.